Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2012

View Archived Issues

Meningitis B vaccine is immunogenic in adolescents in phase IIb/III trial

Novel dual modulators of serotonin 5-HT2A and dopamine D3 receptors reported

Idera Pharmaceuticals reports phase Ib data on IMO-2055

Chiesi Farmaceutici patents new muscarinic acetylcholine M receptor antagonists

Everolimus improves survival of patients with gastrointestinal cancer

FDA lifts clinical hold placed on Arikace program

Traditional medicine ameliorates chemotherapy-induced nausea and vomiting

Novel constrained vaccines created in Australia

CHMP issues opinion on Folotyn

Capstone Therapeutics terminates development of two products

New statin derivatives reported by NicOx

Medicago expands on rabies vaccine development

Novartis announces CHMP opinion on Signifor

Novel glucagon analogues described

Sandoz begins two phase III trials of biosimilars

Novel GlyT-1 inhibitors reported by Roche

MEK-162 investigated in biliary tract cancer

Enrollment opens in phase III PRESENT study of NeuVax

Intravenous Bonalon approved in Japan

EMA reviews Gilenya following reports of heart problems in patients

OncoSec Medical updates corporate progress

EMA recommends marketing suspension for meprobamate-containing medicines

FDA committee against approval of vaginal gel to reduce preterm birth

FDA offers guidance on EpiCept's AmiKet program

Study investigates tasquinimod/cabazitaxel combination in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.